MyFinsight
Home
Blog
About
Cash and cash
equivalents
$219,766K
(-22.05%↓ Y/Y)
Short-term marketable
securities
$167,891K
(195.18%↑ Y/Y)
Receivables from
collaborative arrangements
$20,381K
(-7.02%↓ Y/Y)
Other prepaid and
current assets
$8,624K
(54.80%↑ Y/Y)
Total current assets
$416,662K
(13.75%↑ Y/Y)
Other assets
$25,177K
(-2.30%↓ Y/Y)
Operating lease assets
$21,926K
(-17.24%↓ Y/Y)
Property and equipment,
net
$5,169K
(-22.17%↓ Y/Y)
Restricted cash
$836K
(0.00%↑ Y/Y)
Total assets
$469,770K
(10.27%↑ Y/Y)
Total liabilities and
shareholders' equity
$469,770K
(10.27%↑ Y/Y)
Total shareholders'
equity
$289,705K
(28.84%↑ Y/Y)
Unrecognized tax benefits
$88,486K
(13.73%↑ Y/Y)
Future royalty payment
contingency
$32,795K
(3.65%↑ Y/Y)
Total current
liabilities
$30,766K
(-43.69%↓ Y/Y)
Long-term operating lease
liabilities
$27,774K
(-21.90%↓ Y/Y)
Other long-term
liabilities
$244K
(-84.24%↓ Y/Y)
Accumulated deficit
-$870,458K
(5.82%↑ Y/Y)
Accumulated other
comprehensive income (loss)
-$76K
(-660.00%↓ Y/Y)
Additional paid-in capital
$1,160,238K
(0.97%↑ Y/Y)
Operating lease
liabilities
$10,795K
(-0.93%↓ Y/Y)
Accrued general and
administrative expenses
$8,816K
(258.52%↑ Y/Y)
Accrued
personnel-related expenses
$7,825K
(7.80%↑ Y/Y)
Accrued clinical and
development expenses
$2,395K
(-36.69%↓ Y/Y)
Accounts payable
$652K
(-61.07%↓ Y/Y)
Other accrued
liabilities
$283K
(-84.83%↓ Y/Y)
Ordinary shares, 0.00001
par value per share...
$1K
(0.00%↑ Y/Y)
Back
Back
Balance Sheet
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)
source: myfinsight.com